Top News
-
September 26, 2023Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of Anti-LILRB2 Antibody ES009 in AustraliaLearn More -
March 17, 2023Elpiscience to Present at BIO-Europe Spring 2023 in BaselLearn More -
February 27, 2023Elpiscience Announces First Patient Dosed for Phase 1 Clinical Trial of First-in-Class Anti-CD39xTGF-β Bispecific Antibody ES014Learn More
Our Pipeline
Elpiscience has a robust pipeline of globally innovative cancer immunotherapies, covering a wide range of oncology targets. Through internal R&D expertise and partnerships with global biopharmaceutical companies, Elpiscience endeavors to advance at least one innovative program into the clinic each year.
Learn More
Our Science
Elpiscience has established comprehensive R&D capabilities including proprietary monoclonal and bispecific antibody discovery, translational research, clinical development. Our integrated R&D engine enables us to advance our innovative programs rapidly and cost-effectively.
Learn More
Partnering
Elpiscience collaborates with global biopharmaceutical and biotechnology companies, academic institutions, and clinicians to accelerate the development of innovative cancer immunotherapies.
Careers
Elpiscience fosters an inclusive work environment comprised of diverse, committed, and highly accomplished professionals. Together, we live Elpiscience’s values as we advance scientific innovation and develop transformative medicines that improve cancer patients’ lives.
Learn More
